2025年，香港金融市场展现出令人瞩目的复苏动能与战略韧性。 在这背后，除了上市新股数量与募资额大增外，九成新股溢价发行、基石投资者认购数额创历史新高、打新的人数持续回升等一系列细节，也 成为过去一年港股IPO"王者归来"最好的"注脚"。 近日，沙利文、捷利交易宝、头豹联合发布的《2025年香港IPO市场及二级市场白皮书》(简称《白皮书》)显示，2025年香港IPO市场火热，多 维度发行数据足以证明： 90%的新股选择溢价发行；大多数新股采取招股区间的上限价定价；新股首日破发率降至三成以下；上市后股价翻倍者比比皆是；参与港股打 新的人数持续回升；百倍认购、千倍认购不再稀奇，甚至创下新股万倍认购的记录。 同时，基石投资者参与新股的金额也创出历史新高。2025年，78.07%的IPO新股引入了基石投资者，较上一年提升11.07个百分点，基石投资总 额约1065.96亿港元，创下历史新高。瑞银、Jane Street、GIC Private Limited、施罗德等外资机构尤为活跃。 九成新股溢价发行 据LiveReport大数据统计，2025年114家IPO公司中，72家有上市前估值数据，占比63.16%。 从发 ...

Industry Overview - The report highlights the recent release of the "Implementation Regulations of the Drug Administration Law of the People's Republic of China" and the issuance of opinions by nine departments to promote high-quality development in the drug retail industry [21][23][25] - The sixth batch of national procurement for high-value medical consumables has been opened for bidding, indicating ongoing efforts to regulate and enhance the medical supply chain [21][22] Industry Data - In December, the Consumer Price Index (CPI) for healthcare was 101.8, with a year-on-year increase of 1.8% and a month-on-month increase of 0.1% [26] - The Producer Price Index (PPI) for pharmaceutical manufacturing was 96.1, showing a year-on-year decrease of 3.9% and a month-on-month decrease of 0.2% [37] - For the entire year of 2025, the cumulative operating income of the pharmaceutical manufacturing industry was 24,870.0 billion, a year-on-year decrease of 1.2%, while the cumulative total profit was 3,490.0 billion, a year-on-year increase of 2.7% [39] Company Announcements - Hengrui Medicine received drug registration approval and had several drugs included in the list of breakthrough therapy designations, indicating a strong pipeline and regulatory progress [62][67] - Zai Lab entered a global strategic cooperation and licensing agreement with AbbVie for the development and commercialization of ZG006, which includes significant upfront and milestone payments [68] - Rongchang Bio signed an exclusive licensing agreement with AbbVie for RC148, a dual-specific antibody drug, which includes substantial upfront and potential milestone payments [69] Market Performance - In January, the Shanghai Composite Index rose by 3.76%, while the Shenzhen Component Index increased by 5.03%. The SW Pharmaceutical and Biological Index rose by 3.14%, with all sub-sectors showing positive growth [74] - The SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) was 50.97, with a valuation premium of 258% relative to the CSI 300 [77] Monthly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, particularly in light of recent developments in brain-computer interfaces and AI applications [84] - The report maintains a "neutral" rating for the industry and recommends a "buy" rating for Hengrui Medicine and an "accumulate" rating for WuXi AppTec [84]

Core Viewpoint - Heng Rui Medicine (01276) has seen its stock price increase by over 3%, currently trading at HKD 68.75 with a transaction volume of HKD 71.27 million, following the acceptance of two drug application submissions by the National Medical Products Administration (NMPA) [1][1]. Group 1: Drug Application Acceptance - The company's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received an acceptance notice from the NMPA for the drug application of HR20013, an injectable formulation of Phosphorlorapitant Palonosetron, aimed at preventing nausea and vomiting induced by moderately emetogenic chemotherapy [1][1]. - The application for HR20013 is based on a multicenter, randomized, double-blind, positive-controlled Phase III clinical trial (HR20013-302) evaluating its efficacy and safety [1][1]. Group 2: Innovative Drug Submission - Heng Rui Medicine and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., also received an acceptance notice from the NMPA for a new indication of the innovative drug, injectable Camrelizumab, in combination with Apatinib Mesylate tablets [1][1]. - This application is based on a randomized controlled, open-label, multicenter Phase III clinical trial (SHR-1210-III-336 study) comparing the efficacy and safety of Camrelizumab and Apatinib combined with TACE versus TACE alone in patients with unresectable hepatocellular carcinoma [1][1].

每经AI快讯，恒瑞医药(01276.HK)涨超3%，截至发稿，涨3%，报68.75港元，成交额7126.63万港元。 ...

Core Viewpoint - Heng Rui Medicine (600276) has seen its stock price increase by over 3%, currently trading at 68.75 HKD with a transaction volume of 71.27 million HKD, following the acceptance of two drug application submissions by the National Medical Products Administration (NMPA) [1] Group 1: Drug Approvals - The company's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received an acceptance notice from the NMPA for the marketing authorization application of HR20013, an injectable drug for preventing nausea and vomiting caused by moderately emetogenic anticancer drugs, based on a Phase III clinical trial [1] - Heng Rui Medicine and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., also received an acceptance notice for the marketing authorization application of a new indication for the innovative drug SHR-1210 (injectable carrelizumab) in combination with apatinib, based on a Phase III clinical trial comparing the efficacy and safety of the combination treatment against TACE alone for patients with unresectable hepatocellular carcinoma [1]

Core Viewpoint - Heng Rui Medicine (01276) has seen its stock price increase by over 3%, currently trading at HKD 68.75, with a transaction volume of HKD 71.27 million [1] Group 1: Regulatory Approvals - The company's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration (NMPA) for the marketing authorization application of HR20013, an injectable drug for preventing nausea and vomiting caused by moderately emetogenic anticancer drugs [1] - The application for HR20013 is based on a multicenter, randomized, double-blind, positive-controlled Phase III clinical trial (HR20013-302) evaluating its efficacy and safety [1] Group 2: New Indications for Existing Drugs - Heng Rui Medicine and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., have also received a "Notice of Acceptance" from the NMPA for the marketing authorization application of a new indication for the innovative drug, SHR-1210 (injectable carrelizumab) in combination with apatinib mesylate tablets [1] - This application is based on a randomized controlled, open-label, multicenter Phase III clinical trial (SHR-1210-III-336 study) comparing the efficacy and safety of carrelizumab and apatinib combined with TACE versus TACE alone in patients with unresectable hepatocellular carcinoma [1]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, indicating a positive outlook based on ongoing technological innovation and demand growth [5][6]. Core Insights - The total market value of pharmaceutical stocks held by public funds decreased from 397.7 billion to 316.1 billion yuan, reflecting a decline of 2.58% from Q3 2025 to Q4 2025. The proportion of pharmaceutical stocks in all public fund holdings fell to 7.95%, down 2.58 percentage points from the previous quarter [6][9]. - The highest proportion of holdings in the pharmaceutical sector is in chemical preparations, other biological products, and medical research outsourcing, which accounted for 37.5%, 20.9%, and 16.4% of the total holdings, respectively [6][13]. - The top five pharmaceutical stocks by market value held by public funds in Q4 2025 were: Heng Rui Medicine (32 billion), WuXi AppTec (30.6 billion), Innovent Biologics (16.7 billion), Mindray Medical (15.2 billion), and CanSino Biologics (10.8 billion) [6][24]. Summary by Sections 1. Pharmaceutical Holdings Proportion - The proportion of pharmaceutical stocks held by public funds decreased to 7.95% in Q4 2025, down from Q3 2025, with a notable decline in non-pharmaceutical public fund holdings [9][10]. 2. Market Value of Pharmaceutical Sub-sectors - In Q4 2025, the market value of pharmaceutical sub-sectors held by public funds was as follows: 1. Chemical preparations: 118.6 billion yuan (37.5%) 2. Other biological products: 66 billion yuan (20.1%) 3. Medical research outsourcing: 51.7 billion yuan (16.4%) 4. Medical devices: 33.3 billion yuan (10.5%) 5. Medical consumables: 9.8 billion yuan (3.1%) [13][12]. 3. Public Fund Heavy Holdings - The number of public funds holding the top five pharmaceutical stocks in Q4 2025 was as follows: Heng Rui Medicine (507 funds), WuXi AppTec (448 funds), Mindray Medical (204 funds), Innovent Biologics (202 funds), and BeiGene (162 funds) [17][21]. - The market value growth of public fund heavy holdings in Q4 2025 saw significant increases for Heng Rui Medicine (+20.1 billion), WuXi AppTec (+5.7 billion), China National Pharmaceutical Group (+5 billion), Yingke Medical (+2.2 billion), and Yuyue Medical (+1.8 billion) [28].

智通财经APP讯，恒瑞医药(01276)发布公告，于2026年2月4日，该公司斥资931.7万元回购16.5万股A 股。 ...

Group 1 - The core point of the article is that Heng Rui Medicine (01276.HK) announced a share buyback on February 4, 2026, spending RMB 9.317 million to repurchase 165,000 A-shares at a price range of RMB 56.25 to 57.09 per share [1][1][1] Group 2 - Heng Rui Medicine's share buyback reflects the company's strategy to enhance shareholder value and confidence in its stock performance [1] - The company has also received acceptance for the marketing authorization application of "Injectable Phosphorlorapitant Palonosetron" from Fujian Shengdi Medicine [1]